NCT00506805

Brief Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P50-P75 for phase_1 cancer

Timeline
Completed

Started Jun 2007

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 24, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 25, 2007

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2010

Completed
Last Updated

May 28, 2012

Status Verified

May 1, 2012

Enrollment Period

2.8 years

First QC Date

July 24, 2007

Last Update Submit

May 25, 2012

Conditions

Cancer

Keywords

solid tumor malignancy; Hsp90

Outcome Measures

Primary Outcomes (1)

  • adverse events and other safety assessments

    continuous

Secondary Outcomes (1)

  • tumor response measured by X-rays or scans

    after every 2 cycles

Study Arms (1)

Single Arm

EXPERIMENTAL
Drug: SNX-5422

Interventions

SNX-5422DRUG

dose escalated, tablets every other day; undetermined duration until disease progression

Single Arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \>18 years old
  • histologically confirmed solid tumor malignancy
  • refractory to available therapy or for which no therapy is available
  • adequate organ function

You may not qualify if:

  • CNS malignancy
  • significant GI disease
  • at risk for prolonged QT interval

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Pfizer Investigational Site

Scottsdale, Arizona, 85258, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37203, United States

Location

Related Links

MeSH Terms

Conditions

Neoplasms

Interventions

SNX-5422

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 24, 2007

First Posted

July 25, 2007

Study Start

June 1, 2007

Primary Completion

March 1, 2010

Study Completion

March 1, 2010

Last Updated

May 28, 2012

Record last verified: 2012-05

Locations

US(2)